Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 


 
 Table of Contents  
ORIGINAL ARTICLE
Year : 2014  |  Volume : 10  |  Issue : 7  |  Page : 160-166

Prognostic value of circulating C-reactive protein levels in patients with non-small cell lung cancer: A systematic review with meta-analysis


Department of Medical Oncology, Zhejiang Key Laboratory of Diagnosis and Treatment Technology on Thoracic Oncology (Lung and Esophagus), Zhejiang Cancer Hospital, Hangzhou 310022, China

Date of Web Publication29-Nov-2014

Correspondence Address:
Xinmin Yu
Department of Medical Oncology, Zhejiang Key Laboratory of Diagnosis and Treatment Technology on Thoracic Oncology (Lung and Esophagus), Zhejiang Cancer Hospital, 38 Guangji Road, Hangzhou 310022
China
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0973-1482.145854

Rights and Permissions
 > Abstract 

Background: The clinical and prognostic significance of C-reactive protein (CRP) in nonsmall-cell lung cancer (NSCLC) remains inconsistent. To clarify a precise determinant of the clinical significance of CRP, we conducted a systematic review and meta-analysis to evaluate the overall risk of elevated CRP for survival in NSCLC.
Materials and Methods: Related studies were identified and evaluated for quality through multiple search strategies. Data were collected from studies comparing overall survival in patients with elevated CRP levels and those having lower levels. The meta-analysis was performed by Review Manager version 5.2 (RevMan; the Cochrane Collaboration, Oxford, England). The pooled hazard ratios (HRs) and 95% confidence intervals (CI) were calculated employing fixed- or random-effects models depending on the heterogeneity of the included trials.
Results: Eight eligible studies involved 1649 patients were ultimately identified. Combined HRs suggested that elevated CRP had an unfavorable impact on survival of patients with NSCLC. The HRs (95% CI) was 1.55 (1.19-2.01) overall, 1.78 (1.33-2.38) in Asian patients, 1.33 (1.00-1.77) in non-Asian patients, 1.78 (1.47-2.15) in primary resectable NSCLC, 1.28 (0.95-1.73) in primary unresectable NSCLC, 1.78 (1.33-2.38) in group of cut-off value <5 mg/L, 1.33 (1.00-1.77) in group of cut-off value ≥10 mg/L.
Conclusions: With the available evidence, CRP might serve as an efficient prognostic indicator in NSCLC. This marker should be taken into consideration in the development of new diagnostic and therapeutic program for NSCLC.

Keywords: C-reactive protein, lung cancer, meta-analysis, prognosis


How to cite this article:
Jin Y, Sun Y, Shi X, Zhao J, Shi L, Yu X. Prognostic value of circulating C-reactive protein levels in patients with non-small cell lung cancer: A systematic review with meta-analysis. J Can Res Ther 2014;10, Suppl S3:160-6

How to cite this URL:
Jin Y, Sun Y, Shi X, Zhao J, Shi L, Yu X. Prognostic value of circulating C-reactive protein levels in patients with non-small cell lung cancer: A systematic review with meta-analysis. J Can Res Ther [serial online] 2014 [cited 2019 Aug 22];10:160-6. Available from: http://www.cancerjournal.net/text.asp?2014/10/7/160/145854


 > Introduction Top


Lung cancer continues to be the most frequently diagnosed cancer and the leading cause of cancer-related mortality worldwide, accounting for almost 1.4 million deaths annually. [1] The overall 5-year survival for lung cancer remains at about 15%, which is lower than the mortality rate for other common malignancies, including colon, breast, and prostate cancer. Nonsmall-cell lung cancer (NSCLC) accounts for approximately 80% of lung cancer diagnoses, and the most common forms of NSCLC include adenocarcinoma, squamous cell carcinoma. [2],[3] More than half of NSCLC patients present with advanced, unresectable disease (stage IIIB/IV), despite recent advances in the multidisciplinary treatment, such tumors remain incurable and carries a poor prognosis. [4] Although tumor-node-metastasis (TNM) staging system, age, performance status and weight loss are the most significant clinical parameters to be considered on NSCLC prognosis, the predictive powers of these factors are not optimal. [5] A promising breakthrough to improve the outcome for NSCLC patients is the application of validated biomarkers into clinical management. As a consequence, it is crucial to identify more accurate prognosis and predictive markers that can guide treatment strategies and monitor disease progress, and eventually achieve better prognosis for NSCLC patients.

Chronic airway inflammation plays an important role in the alternations of bronchial epithelium and lung microenvironment, provoking a milieu conducive to pulmonary carcinogenesis and progression of lung cancer. The relationships between inflammation and lung cancer are complex and not yet fully understood. There is mounting evidence suggesting that the association between inflammation and lung cancer is not coincidental, but may indeed be causal. [6],[7],[8] C-reactive protein (CRP) is a representative sensitive marker for inflammatory status which not only display rapid and pronounced rise of its plasma concentration in response to acute inflammation, infection, and tissue damage, [9],[10],[11] but also act as an indicator of chronic inflammation being related to many diseases, including cancers. [12] Serum CRP has been found to be elevated in patients with many malignancies, including lung, [13] breast, [14] pancreas, [15] esophagus, [16] liver, [17] the biliary tract, [18] stomach, [19] and ovary. [20] These results may suggest that high inflammation level can be associated with a higher risk of cancer. During the past decade, researchers focused on extending the clinical use of circulating CRP to the prediction of malignancies. The prognostic significance of serum CRP has also been demonstrated in many forms of cancer, such as colorectal, [21] ovarian, [22] esophageal, [23] pancreatic, [24] and hepatocellular. [25]

Until date, controversy exists concerning the correlation between circulating CRP and prognostic value with respect to NSCLC. Some studies reported that the high expression of serum CRP was correlated with unfavorable prognosis, [26],[27] while some others did not show any significant link between CRP and NSCLC survival. [28],[29] In this study, we performed an updated meta-analysis to give a comprehensive evaluation on the prognostic role of CRP in NSCLC.


 > Materials and methods Top


Searching method and study selection

Two investigators (Yan Sun and Xun Shi) independently searched PubMed and Embase databases using the following search terms "CRP OR inflammation," and "NSCLC." Furthermore, references of retrieved articles and reviews were manually screened for additional studies. Studies were considered eligible if they met the following criteria: (i) Baseline CRP values were measured, (ii) information on survival were provided (studies investigating response rates only were excluded), (iii) when the same author reported results from the same patient population in more than one publication, only the most recent report, or the most complete one, was included. Studies were excluded based on the following criteria: They were (i) Review articles or letters, (ii) non-English-language articles, (iii) laboratory studies, (iv) studies in which necessary data were not provided.

Data extraction and study quality assessment

Two investigators (Jun Zhao and Lei Shi) independently identified eligible trials. When the two investigators discovered different results, an independent expert in oncology made the final decision of study conclusions. Information collected from these studies included first author, year of publication, country of origin, histology, disease stage, sample size, cut-off value, and hazard ratios (HRs) of CRP for overall survival (OS) with its 95% confidence intervals (95% CI) and P value. When HRs were not reported in collected papers, we computed HRs and its 95% CI assuming an exponential distribution of the survival curve. In the estimation of HRs, we applied the published methodology [30] on the graphic software package Engauge (The Engauge is an open source software. We used Engauge Digitizer 4.1 [Qt] in this research) to estimate the logarithm transformed HR and variance from the Kaplan-Meier curves.

We systematically assessed the quality of all the studies included as per the crucial review checklist of the Dutch Cochrane Centre proposed by MOOSE. [31] The key points of the current checklist include: (i) Clear definition of study population and origin of country; (ii) clear definition of study design; (iii) clear definition of outcome assessment, OS, cancer-specific survival and progression-free survival; (iv) clear definition of cut-off for CRP or clear definition of log of CRP and (v) sufficient period of follow-up. Those studies that do not mention all these 5 points were excluded to avoid compromising the quality of a meta-analysis. We performed this meta-analysis in accordance with the guidelines of the Preferred Reporting Items for Systematic Review and Meta-analyses statement.

Statistical analysis

We first tested the statistical heterogeneity between studies (meaningful differences between studies) using the Chi-squared Q-test based on a fixed-effect model. The studies were considered heterogeneous when the P value of the Chi-squared Q-test was <0.10, or when I2 was >50%. When the analyses showed heterogeneity between different studies, a random-effect model was applied to accommodate the heterogeneity. [32] Potential publication bias was assessed with the Begg's test and Egger's test, and graphically presented by funnel plots. All statistical analysis was performed by Review Manager version 5.2 (RevMan; the Cochrane Collaboration, Oxford, England). An HR >1 was regarded as a risk factor for worse survival in patients with elevated CRP serum levels. A two-sided P < 0.05 was considered as significant for all analysis except heterogeneity tests.


 > Results Top


Study selection and characteristics

The selection steps are summarized in the flow chart shown in [Figure 1]. According to the searching strategies, a total of 238 Studies were identified. After a series of screening based on the inclusion/exclusion criteria mentioned above, 8 publications were eventually eligible for the meta-analysis. [26],[ 29],[ 33],[34],[35],[36],[37],[38] All these studies were published in peer-reviewed journals.
Figure 1: Study flow chart for the process of selecting the eligible publications

Click here to view


A summary of the study characteristics and clinical outcomes is provided in [Table 1]. The data from 8 studies, which involved a total of 1649 patients from the Netherlands, Chinese, Japan, Greece, United Kingdom, and Sweden, were collected. In these eight studies, CRP values were analyzed by the same means in each study. CRP levels were dealt as a dichotomous variable, with different cut-off values. Six studies reported HRs, and the other two studies presented survival curves.{Table 1}

Effect of elevated C-reactive protein on overall survival in overall patients

The results of primary pooled statistics indicated a significant association between elevated CRP and poor OS (HR = 1.55, 95% 1.19-2.01, P = 0.001) based on random-effects model, due to significant heterogeneity (χ2 = 50.09, P < 0.01; I2 = 86%) [Figure 2].
Figure 2: Forest plots in unselected patients. Hazard ratios with 95% confidence interval of overall survival for high C-reactive protein levels as compared with low levels

Click here to view


Effect of elevated C-reactive protein on overall survival in subgroup analyses

Subgroup analyses were performed by stratifying the included studies by "country of origin," "TNM stage" and "cut-off value."

When stratified by "country of origin", the "Asian" group showed a significant association between elevated CRP and poor OS (HR = 1.78, 95% CI 1.33-2.38, P = 0.0001) [Figure 3]a. The "Non-Asian" group also showed an association between elevated CRP and poor OS (HR = 1.33, 95% CI 1.00-1.77, P = 0.05), but the association was not statistically significant [Figure 3]b.
Figure 3: Forest plots in patients of subgroups. Hazard ratios and 95% confidence intervals of overall survival for high C-reactive protein levels as compared with low levels in (a) the "Asian" group; (b) the "Non-Asian" group; (c) the "primary resectable nonsmall-cell lung cancer (NSCLC)" group; (d) the "primary unresectable NSCLC" group; (e) the cut-off value "≥10 mg/L" group; (f) the cut-off value "<5 mg/L" group

Click here to view


When stratified by "TNM stage", the "primary resectable NSCLC" group showed a significant association between elevated CRP and poor OS (HR = 1.78, 95% CI 1.47-2.15, P < 0.00001) [Figure 3]c. The "primary unresectable NSCLC" group showed no significant association between elevated CRP and poor OS (HR = 1.28, 95%CI 0.95-1.73, P = 0.11) [Figure 3]d.

When stratified by "cut-off value", the "≥10 mg/L" group showed an association between elevated CRP and poor OS (HR = 1.33, 95% CI 1.00-1.77, P = 0.05), but the association was not statistically significant [Figure 3]e. The "<5 mg/L" group showed a significant association between elevated CRP and poor OS (HR = 1.78, 95% CI 1.33-2.38, P = 0.0001) [Figure 3]f.

Publication bias

Publication bias of the included studies was evaluated by funnel plots. No publication bias was observed in the meta-analysis [Figure 4].
Figure 4: Funnel plots in unselected patients of overall survival

Click here to view



 > Discussion Top


The role of inflammation in the development of cancer was first revealed in 1863, when Virchow identified leucocyte infiltration in neoplastic tissues that led him to hypothesize that the sites of chronic inflammation were the origin of malignancies. [39] Since then, chronic inflammation of either infectious or noninfectious causes is demonstrated to contribute to about 1 in 4 of all cancer cases. [40] Until now, several such links were extensively proven: Epstein-Barr virus infection for nasopharyngeal carcinoma, [41] liver fluke and primary sclerosing cholangitis for cholangiocarcinoma, [42] infection with hepatitis virus B and hepatitis virus C for hepatocellular carcinoma, [43] UV irradiation-associated skin inflammation for melanoma, [44] Helicobacter pylori bacterial infection for gastric carcinoma, [45] human papilloma virus infection for cervical carcinoma, [46] Barrett's esophagus for esophageal carcinoma, [47] inflammatory bowel diseases for colorectal carcinoma, [48] and inflammation caused by asbestos, infection, smoking and silica for lung cancer. [49] CRP, a representative and sensitive protein that is widely used for the clinical diagnosis of systemic inflammation and is measured by means of reliable standardized assays, shows promise as a potential biomarker for malignancies. CRP was first discovered in 1930 by Tillet and Francis, when they identified this protein in the blood plasma of patients during the acute phase of pneumococcal pneumonia, and named it according to its high binding affinity to the pneumococcal C polysaccharide. [50] CRP is produced solely by hepatocytes and the plasma half-life of CRP is constant under all conditions of health and disease. [51] Therefore, circulating CRP levels will always closely reflect the degree of tissue inflammation.

In this systemic review with meta-analysis, we have combined 8 published studies including 1649 patients with NSCLC to yield summary statistics that indicate that the increased circulating CRP level has a significant association with poor OS in patients with NSCLC. We did further subgroup analyses by dividing the included studies according to "country of origin," "TNM stage" and "cut-off value." We found that the correlation was existed in both Asian and non-Asian study populations. However, the combined HR (1.78) for Asian populations was larger than the combined HR (1.33) for non-Asian populations. This may be explained by the different "cut-off value" between the Asian studies and the non-Asian studies. As we can see in the [Table 1], the four studies conducted in Asian countries all selected "<5 mg/L" as the cut-off value for CRP, and the other four studies conducted in non-Asian countries all selected "≥10 mg/L" as the cut-off value.

The same result was found when the studies were stratified by "cut-off value" for CRP. The combined HR (1.78) for the cut-off value <5 mg/L group was larger than the combined HR (1.33) for the cut-off value ≥10 mg/L group. In the past, circulating CRP levels under 10 mg/L have been regarded as nonmeaningful. During this decade, with the development of a high sensitivity technique, a minor elevation of CRP reflecting chronic low-grade inflammation shows clinically significant. Several studies have revealed an association between minor elevated CRP (3-10 mg/L) and the risk of developing cancers. [52] Considering that this meta-analysis based on retrospective studies, we suggest that more prospective studies need to be conducted to confirm the optimal cut-off value of CRP to predict prognosis for NSCLC.

In addition, subgroup analyses showed that when stratified by "TNM stage", significant association between elevated CRP and poor OS existed in the "primary resectable NSCLC" group (HR = 1.78, 95% CI 1.47-2.15, P < 0.00001). However, no significant association was observed in the "primary unresectable NSCLC" group (HR = 1.28, 95% CI 0.95-1.73, P = 0.11). It is possible that the result in the latter group could have been influenced by the heterogeneity among the three studies included. Heterogeneity might be contributed by the baseline characteristics of the patients, the cut-off value, palliative treatment they have received, and the duration of follow-up. Therefore, the result was tempered, and more research is urgently needed to investigate this doubt.

The underlying molecular mechanism by which circulating CRP is associated with worse outcome of NSCLC is still uncertain. One explanation is that cancer cells can prompt the production of inflammatory proteins. Experimental studies showed that NSCLC cell lines can produce inflammatory factors, such as interleukin-6 (IL-6), IL-8, and tumor necrotic factor-α. [53],[54] Other possible reasons are (1) causality: Elevated CRP levels cause cancer, (2) reverse causality: Occult cancer increases CRP levels, (3) or confounding: A third factor, such as inflammation, increases both CRP levels and the risk of cancer. [55]

There are some limitations of the present meta-analysis that should be noted. First, all data were extracted from published studies, which might result in publication bias and selection bias. Second, due to the lack of relevant prospective study, all the included studies were retrospective. Third, the analysis was based on summary data rather than individual patient data, which tended to overestimate treatment effects. Therefore, the results must be interpreted cautiously when used in clinical practice.


 > Conclusions Top


Our meta-analysis demonstrated that the circulating CRP levels can be used as a useful prognostic predictor for survival in NSCLC. Serum CRP measurements are simple, rapid, cost-effective, and available in daily practice. CRP-lowering agents may have promising roles for the prevention and therapy of NSCLC. More large-scale, high-quality and prospective studies are needed to give more convincing evidence in the future.


 > Acknowledgments Top


This work was supported by Wu Jie Ping Medical Foundation (Grant No. 320.6750.13393).

 
 > References Top

1.
Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.  Back to cited text no. 1
    
2.
Chheang S, Brown K. Lung cancer staging: Clinical and radiologic perspectives. Semin Intervent Radiol 2013;30:99-113.  Back to cited text no. 2
    
3.
Chen W, Zheng R, Zhang S, Zou X, Zhao P, He J. Lung cancer incidence and mortality in China, 2009. Thorac Cancer 2013;4:102-8.  Back to cited text no. 3
    
4.
Socinski MA, Evans T, Gettinger S, Hensing TA, Sequist LV, Ireland B, et al. Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer, 3 rd ed: American college of chest physicians evidence-based clinical practice guidelines. Chest 2013;143:e341S-68.  Back to cited text no. 4
    
5.
Pore MM, Hiltermann TJ, Kruyt FA. Targeting apoptosis pathways in lung cancer. Cancer Lett 2013;332:359-68.  Back to cited text no. 5
    
6.
Zheng Y, Lin Y, Situ D, Jiang L, Su X, Long H. Analysis of differently expressed proteins involved in metastatic niche of lung. Thorac Cancer 2013;4:385-94.  Back to cited text no. 6
    
7.
Cho WC, Kwan CK, Yau S, So PP, Poon PC, Au JS. The role of inflammation in the pathogenesis of lung cancer. Expert Opin Ther Targets 2011;15:1127-37.  Back to cited text no. 7
    
8.
Tauler J, Mulshine JL. Lung cancer and inflammation: Interaction of chemokines and hnRNPs. Curr Opin Pharmacol 2009;9:384-8.  Back to cited text no. 8
    
9.
Black S, Kushner I, Samols D. C-reactive Protein. J Biol Chem 2004;279:48487-90.  Back to cited text no. 9
    
10.
Casas JP, Shah T, Hingorani AD, Danesh J, Pepys MB. C-reactive protein and coronary heart disease: A critical review. J Intern Med 2008;264:295-314.  Back to cited text no. 10
    
11.
Pepys MB, Hirschfield GM. C-reactive protein: A critical update. J Clin Invest 2003;111:1805-12.  Back to cited text no. 11
    
12.
Heikkilä K, Ebrahim S, Lawlor DA. A systematic review of the association between circulating concentrations of C reactive protein and cancer. J Epidemiol Community Health 2007;61:824-33.  Back to cited text no. 12
    
13.
Chierakul N, Kanitsap A, Chaiprasert A, Viriyataveekul R. A simple C-reactive protein measurement for the differentiation between tuberculous and malignant pleural effusion. Respirology 2004;9:66-9.  Back to cited text no. 13
    
14.
Blann AD, Byrne GJ, Baildam AD. Increased soluble intercellular adhesion molecule-1, breast cancer and the acute phase response. Blood Coagul Fibrinolysis 2002;13:165-8.  Back to cited text no. 14
    
15.
Basso D, Fabris C, Meani A, Del Favero G, Vianello D, Angonese C, et al. C reactive protein in pancreatic cancer and chronic pancreatitis. Ann Clin Res 1988;20:414-6.  Back to cited text no. 15
    
16.
Guillem P, Triboulet JP. Elevated serum levels of C-reactive protein are indicative of a poor prognosis in patients with esophageal cancer. Dis Esophagus 2005;18:146-50.  Back to cited text no. 16
    
17.
Fabris C, Pirisi M, Soardo G, Falleti E, Pezzetta F, Vitulli D, et al. Value of serum C-reactive protein measurement in the detection of hepatocellular carcinoma superimposed on liver cirrhosis. J Cancer Res Clin Oncol 1994;120:229-32.  Back to cited text no. 17
    
18.
Padillo FJ, Muntane J, Montero JL, Briceño J, Miño G, Solorzano G, et al. Effect of internal biliary drainage on plasma levels of endotoxin, cytokines, and C-reactive protein in patients with obstructive jaundice. World J Surg 2002;26:1328-32.  Back to cited text no. 18
    
19.
Wu CW, Lui WY, P'eng FK, Wang SR. Alterations of humoral immunity in patients with gastric cancer. Asian Pac J Allergy Immunol 1988;6:7-10.  Back to cited text no. 19
    
20.
van der Zee AG, de Cuyper EM, Limburg PC, de Bruijn HW, Hollema H, Bijzet J, et al. Higher levels of interleukin-6 in cystic fluids from patients with malignant versus benign ovarian tumors correlate with decreased hemoglobin levels and increased platelet counts. Cancer 1995;75:1004-9.  Back to cited text no. 20
    
21.
McMillan DC, Canna K, McArdle CS. Systemic inflammatory response predicts survival following curative resection of colorectal cancer. Br J Surg 2003;90:215-9.  Back to cited text no. 21
    
22.
Hefler LA, Concin N, Hofstetter G, Marth C, Mustea A, Sehouli J, et al. Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer. Clin Cancer Res 2008;14:710-4.  Back to cited text no. 22
    
23.
Nozoe T, Saeki H, Sugimachi K. Significance of preoperative elevation of serum C-reactive protein as an indicator of prognosis in esophageal carcinoma. Am J Surg 2001;182:197-201.  Back to cited text no. 23
    
24.
Jamieson NB, Glen P, McMillan DC, McKay CJ, Foulis AK, Carter R, et al. Systemic inflammatory response predicts outcome in patients undergoing resection for ductal adenocarcinoma head of pancreas. Br J Cancer 2005;92:21-3.  Back to cited text no. 24
    
25.
Nagaoka S, Yoshida T, Akiyoshi J, Akiba J, Torimura T, Adachi H, et al. Serum C-reactive protein levels predict survival in hepatocellular carcinoma. Liver Int 2007;27:1091-7.  Back to cited text no. 25
    
26.
O'Dowd C, McRae LA, McMillan DC, Kirk A, Milroy R. Elevated preoperative C-reactive protein predicts poor cancer specific survival in patients undergoing resection for non-small cell lung cancer. J Thorac Oncol 2010;5:988-92.  Back to cited text no. 26
    
27.
Hara M, Matsuzaki Y, Shimuzu T, Tomita M, Ayabe T, Enomoto Y, et al. Preoperative serum C-reactive protein level in non-small cell lung cancer. Anticancer Res 2007;27:3001-4.  Back to cited text no. 27
    
28.
Gioulbasanis I, Georgoulias P, Vlachostergios PJ, Baracos V, Ghosh S, Giannousi Z, et al. Mini Nutritional Assessment (MNA) and biochemical markers of cachexia in metastatic lung cancer patients: Interrelations and associations with prognosis. Lung Cancer 2011;74:516-20.  Back to cited text no. 28
    
29.
Chi PD, Liu W, Chen H, Zhang JP, Lin Y, Zheng X, et al. High-density lipoprotein cholesterol is a favorable prognostic factor and negatively correlated with C-reactive protein level in non-small cell lung carcinoma. PLoS One 2014;9:e91080.  Back to cited text no. 29
[PUBMED]    
30.
Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998;17:2815-34.  Back to cited text no. 30
    
31.
Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: A proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000;283:2008-12.  Back to cited text no. 31
    
32.
Sutton AJ, Abrams KR, Jones DR, Sheldon TR. Methods for Meta-Analysis in Medical Research. Chichester: Wiley; 2000.  Back to cited text no. 32
    
33.
Tomita M, Shimizu T, Ayabe T, Nakamura K, Onitsuka T. Elevated preoperative inflammatory markers based on neutrophil-to-lymphocyte ratio and C-reactive protein predict poor survival in resected non-small cell lung cancer. Anticancer Res 2012;32:3535-8.  Back to cited text no. 33
    
34.
Dehing-Oberije C, Aerts H, Yu S, De Ruysscher D, Menheere P, Hilvo M, et al. Development and validation of a prognostic model using blood biomarker information for prediction of survival of non-small-cell lung cancer patients treated with combined chemotherapy and radiation or radiotherapy alone (NCT00181519, NCT00573040, and NCT00572325). Int J Radiat Oncol Biol Phys 2011;81:360-8.  Back to cited text no. 34
    
35.
Gioulbasanis I, Georgoulias P, Vlachostergios PJ, Baracos V, Ghosh S, Giannousi Z, et al. Mini Nutritional Assessment (MNA) and biochemical markers of cachexia in metastatic lung cancer patients: Interrelations and associations with prognosis. Lung Cancer 2011;74:516-20.  Back to cited text no. 35
    
36.
Hara M, Yonei A, Ayabe T, Tomita M, Nakamura K, Onitsuka T. Postoperative serum C-reactive protein levels in non-small cell lung cancer patients. Ann Thorac Cardiovasc Surg 2010;16:85-90.  Back to cited text no. 36
    
37.
Masago K, Fujita S, Togashi Y, Kim YH, Hatachi Y, Fukuhara A, et al. Clinical significance of pretreatment C-reactive protein in patients with advanced nonsquamous, non-small cell lung cancer who received gefitinib. Oncology 2010;79:355-62.  Back to cited text no. 37
    
38.
Koch A, Fohlin H, Sörenson S. Prognostic significance of C-reactive protein and smoking in patients with advanced non-small cell lung cancer treated with first-line palliative chemotherapy. J Thorac Oncol 2009;4:326-32.  Back to cited text no. 38
    
39.
Balkwill F, Mantovani A. Inflammation and cancer: Back to Virchow? Lancet 2001;357:539-45.  Back to cited text no. 39
    
40.
Hussain SP, Harris CC. Inflammation and cancer: An ancient link with novel potentials. Int J Cancer 2007;121:2373-80.  Back to cited text no. 40
    
41.
Han BL, Xu XY, Zhang CZ, Wu JJ, Han CF, Wang H, et al. Systematic review on Epstein-Barr virus (EBV) DNA in diagnosis of nasopharyngeal carcinoma in Asian populations. Asian Pac J Cancer Prev 2012;13:2577-81.  Back to cited text no. 41
    
42.
Zabron A, Edwards RJ, Khan SA. The challenge of cholangiocarcinoma: Dissecting the molecular mechanisms of an insidious cancer. Dis Model Mech 2013;6:281-92.  Back to cited text no. 42
    
43.
El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012;142:1264-73.e1.  Back to cited text no. 43
    
44.
Singh RK, Gutman M, Reich R, Bar-Eli M. Ultraviolet B irradiation promotes tumorigenic and metastatic properties in primary cutaneous melanoma via induction of interleukin 8. Cancer Res 1995;55:3669-74.  Back to cited text no. 44
    
45.
Yoshida T, Kato J, Inoue I, Yoshimura N, Deguchi H, Mukoubayashi C, et al. Cancer development based on chronic active gastritis and resulting gastric atrophy as assessed by serum levels of pepsinogen and Helicobacter pylori antibody titer. Int J Cancer 2014;134:1445-57.  Back to cited text no. 45
    
46.
Priebe AM. 2012 cervical cancer screening guidelines and the future role of HPV testing. Clin Obstet Gynecol 2013;56:44-50.  Back to cited text no. 46
[PUBMED]    
47.
Cameron AJ, Carpenter HA. Barrett's esophagus, high-grade dysplasia, and early adenocarcinoma: A pathological study. Am J Gastroenterol 1997;92:586-91.  Back to cited text no. 47
    
48.
Jess T, Loftus EV Jr, Velayos FS, Harmsen WS, Zinsmeister AR, Smyrk TC, et al. Risk of intestinal cancer in inflammatory bowel disease: A population-based study from olmsted county, Minnesota. Gastroenterology 2006;130:1039-46.  Back to cited text no. 48
    
49.
Vainio H, Boffetta P. Mechanisms of the combined effect of asbestos and smoking in the etiology of lung cancer. Scand J Work Environ Health 1994;20:235-42.  Back to cited text no. 49
    
50.
Tillett WS, Francis T. Serological reactions in pneumonia with a non-protein somatic fraction of pneumococcus. J Exp Med 1930;52:561-71.  Back to cited text no. 50
    
51.
Vigushin DM, Pepys MB, Hawkins PN. Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease. J Clin Invest 1993;91:1351-7.  Back to cited text no. 51
    
52.
Kushner I, Rzewnicki D, Samols D. What does minor elevation of C-reactive protein signify? Am J Med 2006;119:166.e17-28.  Back to cited text no. 52
    
53.
Matsuguchi T, Okamura S, Kawasaki C, Shimoda K, Omori F, Hayashi S, et al. Constitutive production of granulocyte colony-stimulating factor and interleukin-6 by a human lung cancer cell line, KSNY: Gene amplification and increased mRNA stability. Eur J Haematol 1991;47:128-33.  Back to cited text no. 53
    
54.
Niiya M, Niiya K, Kiguchi T, Shibakura M, Asaumi N, Shinagawa K, et al. Induction of TNF-alpha, uPA, IL-8 and MCP-1 by doxorubicin in human lung carcinoma cells. Cancer Chemother Pharmacol 2003;52:391-8.  Back to cited text no. 54
    
55.
Allin KH, Nordestgaard BG. Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer. Crit Rev Clin Lab Sci 2011;48:155-70.  Back to cited text no. 55
    


    Figures

  [Figure 1], [Figure 2], [Figure 3], [Figure 4]



 

Top
 
 
  Search
 
Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

  >Abstract>Introduction>Materials and me...>Results>Discussion>Conclusions>Acknowledgments>Article Figures
  In this article
>References

 Article Access Statistics
    Viewed2973    
    Printed75    
    Emailed0    
    PDF Downloaded123    
    Comments [Add]    

Recommend this journal


[TAG2]
[TAG3]
[TAG4]